Release date: 2007-07-25 Minimally invasive interventional therapy for cardiovascular diseases has become a popular treatment option due to its advantages such as minimal trauma, high effectiveness, fewer complications, no need for blood transfusions, shorter hospital stays, and the possibility of repeated procedures. However, many patients in China face challenges due to the high cost of imported stents, which can reach tens of thousands of dollars. Fortunately, recent developments in domestic medical technology have brought more affordable and effective alternatives to the market. A large-scale clinical trial involving over 50 hospitals across 20 provinces has demonstrated that high-quality domestic coronary stents are not only cost-effective but also deliver results comparable to their imported counterparts. This study, led by the Department of Cardiology at the General Hospital of the Shenyang Military Region, included more than 2,000 patients with coronary heart disease who were treated with a new biodegradable coating drug-eluting stent. The results showed an effective success rate of over 98%, with significant reductions in restenosis and stent thrombosis after six months. Compared to imported models, the domestic version offers similar performance at about 40% lower cost. These findings have gained international recognition, significantly enhancing the reputation of Chinese-made medical devices. According to official statistics, approximately 1.2 million children are born with birth defects each year in China, including around 150,000 with congenital heart disease. Professor Zhu Xianyang from the Department of Congenital Heart Disease highlighted that factors such as improper medication during pregnancy, viral infections, rubella, genetic predispositions, and environmental influences have contributed to a rising incidence of heart conditions among children in Liaoning. Early intervention is crucial, and with interventional surgery, the cure rate for these cases reaches as high as 98.5%. Historically, the high cost of imported occluders limited access to timely treatment for many children. In some cases, families could not afford the procedure, leading to delayed or missed opportunities for surgery. However, since 2002, the development of domestic ventricular, atrial, and patent ductus arteriosus occluders has broken the country's reliance on foreign imports. These devices are now priced at just 60% of their imported equivalents and have been widely used in clinical settings. Over 3,000 domestic occluders have been successfully implanted, achieving a 98.8% success rate. Their reliability and quality match those of imported products, offering life-changing solutions to thousands of patients across the country. Organic Corn Resistant Dextrin Powder Resistant Corn Dextrin,Resistant Dextrin Fiber,Dietary Soluble Corn Fiber,Soluble Corn Fiber Qingdao Bailong Huichuang Bio-tech Co., Ltd. , https://www.sdblcycn.com